Search

Your search keyword '"Kim, Sung Bae"' showing total 27 results
Start Over Author "Kim, Sung Bae" Journal breast cancer research and treatment
27 results on '"Kim, Sung Bae"'

1. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)

Author

Hwang, Inhwan, Kim, Jeong Eun, Jeong, Jae Ho, Ahn, Jin-Hee, Jung, Kyung Hae, Son, Byung Ho, Kim, Hak Hee, Shin, Junyoung, Lee, Hee Jin, Gong, Gyungyub, and Kim, Sung-Bae

Published
2023
Full Text
View/download PDF

2. Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Author

Moy, Beverly, Oliveira, Mafalda, Saura, Cristina, Gradishar, William, Kim, Sung-Bae, Brufsky, Adam, Hurvitz, Sara A, Ryvo, Larisa, Fagnani, Daniele, Kalmadi, Sujith, Silverman, Paula, Delaloge, Suzette, Alarcon, Jesus, Kwong, Ava, Lee, Keun Seok, Ang, Peter Cher Siang, Ow, Samuel Guan Wei, Chu, Sung-Chao, Bryce, Richard, Keyvanjah, Kiana, Bebchuk, Judith, Zhang, Bo, Oestreicher, Nina, Bose, Ron, and Chan, Nancy

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Capecitabine, Female, Humans, Quality of Life, Quinolines, Receptor, ErbB-2, Neratinib, Metastatic breast cancer, Health-related quality of life, HER2-positive, Receptor, erbB-2, Clinical Sciences, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeTo characterize health-related quality of life (HRQoL) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) from the NALA phase 3 study.MethodsIn NALA (NCT01808573), patients were randomized 1:1 to neratinib + capecitabine (N + C) or lapatinib + capecitabine (L + C). HRQoL was assessed using seven prespecified scores from the European Organisation for Research and Treatment of Cancer Quality Of Life Questionnaire core module (QLQ-C30) and breast cancer-specific questionnaire (QLQ-BR23) at baseline and every 6 weeks. Descriptive statistics summarized scores over time, mixed models evaluated differences between treatment arms, and Kaplan-Meier methods were used to assess time to deterioration in HRQoL scores of ≥ 10 points.ResultsOf the 621 patients randomized in NALA, patients were included in the HRQoL analysis if they completed baseline and at least one follow-up questionnaire. The summary, global health status, physical functioning, fatigue, constipation, and systemic therapy side effects scores were stable over time with no persistent differences between treatment groups. There were no differences in time to deterioration (TTD) for the QLQ-C30 summary score between treatment arms; the hazard ratio (HR) for N + C vs. L + C was 0.94 (95% CI 0.63-1.40). Only the diarrhea score worsened significantly more in the N + C arm as compared to the L + C arm, and this remained over time (HR for TTD for N + C vs. L + C was 1.71 [95% CI 1.32-2.23]).ConclusionIn NALA, patients treated with N + C maintained their global HRQoL over time, despite a worsening of the diarrhea-related scores. These results may help guide optimal treatment selection for HER2-positive MBC.

Published
2021

3. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Author

Turner, Nicholas, Dent, Rebecca A., O’Shaughnessy, Joyce, Kim, Sung-Bae, Isakoff, Steven J., Barrios, Carlos, Saji, Shigehira, Bondarenko, Igor, Nowecki, Zbigniew, Lian, Qinshu, Reilly, Sarah-Jayne, Hinton, Heather, Wongchenko, Matthew J., Kovic, Bruno, Mani, Aruna, and Oliveira, Mafalda

Published
2022
Full Text
View/download PDF

4. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

Author

Dai, Ming Shen, Feng, Yin Hsun, Chen, Shang Wen, Masuda, Norikazu, Yau, Thomas, Chen, Shou Tung, Lu, Yen Shen, Yap, Yoon Sim, Ang, Peter C. S., Chu, Sung Chao, Kwong, Ava, Lee, Keun Seok, Ow, Samuel, Kim, Sung Bae, Lin, Johnson, Chung, Hyun Cheol, Ngan, Roger, Kok, Victor C., Rau, Kun Ming, Sangai, Takafumi, Ng, Ting Ying, Tseng, Ling Ming, Bryce, Richard, Bebchuk, Judith, Chen, Mei Chieh, and Hou, Ming Feng

Published
2021
Full Text
View/download PDF

10. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)

Author

Park, Yeon Hee, Jung, Kyung Hae, Im, Seock-Ah, Sohn, Joo Hyuk, Ro, Jungsil, Ahn, Jin-Hee, Kim, Sung-Bae, Nam, Byung-Ho, Oh, Do Youn, Han, Sae-Won, Lee, Soohyeon, Park, In Hae, Lee, Keun Seok, Kim, Jee Hyun, Kang, Seok Yun, Lee, Moon Hee, Park, Hee Sook, Woo, Sook Young, Jung, Sin-Ho, Ahn, Jin Seok, Im, Young-Hyuck, and Korean Cancer Study Group (KCSG)

Published
2015
Full Text
View/download PDF

12. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Author

Turner, Nicholas, primary, Dent, Rebecca A., additional, O’Shaughnessy, Joyce, additional, Kim, Sung-Bae, additional, Isakoff, Steven J., additional, Barrios, Carlos, additional, Saji, Shigehira, additional, Bondarenko, Igor, additional, Nowecki, Zbigniew, additional, Lian, Qinshu, additional, Reilly, Sarah-Jayne, additional, Hinton, Heather, additional, Wongchenko, Matthew J., additional, Kovic, Bruno, additional, Mani, Aruna, additional, and Oliveira, Mafalda, additional

Published
2021
Full Text
View/download PDF

21. Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer

Author

Lee, Young Joo, primary, Park, Heeseung, additional, Kang, Cheol Min, additional, Gwark, Sung-chan, additional, Lee, Sae Byul, additional, Kim, Jisun, additional, Chung, Il Yong, additional, Ko, Beom Seok, additional, Kim, Hee Jeong, additional, Kim, Sung-Bae, additional, Ahn, Seung Do, additional, Gong, Gyungyub, additional, Son, Byung Ho, additional, Ahn, Sei-Hyun, additional, and Lee, Jong Won, additional

Published
2019
Full Text
View/download PDF

22. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01

Author

Im, Seock-Ah, primary, Lee, Keun Seok, additional, Ro, Jungsil, additional, Lee, Eun Sook, additional, Kwon, Youngmee, additional, Ahn, Jin-Hee, additional, Ahn, Jin Seok, additional, Kim, Jee Hyun, additional, Kang, Han Sung, additional, Shin, Kyung Hwan, additional, Noh, Dong-Young, additional, Park, In-Ae, additional, Kim, Sung-Bae, additional, Im, Young Hyuck, additional, and Ha, Sung Whan, additional

Published
2011
Full Text
View/download PDF

23. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)

Author

Kim, Jeong Eun, primary, Ahn, Jin-Hee, additional, Jung, Kyung Hae, additional, Kim, Sung-Bae, additional, Kim, Hwa Jung, additional, Lee, Keun-Suk, additional, Ro, Jung-Sil, additional, Park, Yun-Hee, additional, Ahn, Jin-Suk, additional, Im, Young-Hyk, additional, Im, Seock-Ah, additional, Lee, Moon-Hee, additional, and Kim, Si-Young, additional

Published
2010
Full Text
View/download PDF

27. Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.

Author

Dent R, Oliveira M, Isakoff SJ, Im SA, Espié M, Blau S, Tan AR, Saura C, Wongchenko MJ, Xu N, Bradley D, Reilly SJ, Mani A, and Kim SB

Subjects
Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Double-Blind Method, Female, Humans, Paclitaxel adverse effects, Phosphatidylinositol 3-Kinases, Piperazines, Pyrimidines, Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms drug therapy
Abstract

Purpose: In LOTUS (NCT02162719), adding the oral AKT inhibitor ipatasertib to first-line paclitaxel for locally advanced/metastatic triple-negative breast cancer (aTNBC) improved progression-free survival (PFS; primary endpoint), with an enhanced effect in patients with PIK3CA/AKT1/PTEN-altered tumors (FoundationOne next-generation sequencing [NGS] assay). We report final overall survival (OS) results., Methods: Eligible patients had measurable previously untreated aTNBC. Patients were stratified by prior (neo)adjuvant therapy, chemotherapy-free interval, and tumor immunohistochemistry PTEN status, and were randomized 1:1 to paclitaxel 80 mg/m 2 (days 1, 8, 15) plus ipatasertib 400 mg or placebo (days 1-21) every 28 days until disease progression or unacceptable toxicity. OS (intent-to-treat [ITT], immunohistochemistry PTEN-low, and PI3K/AKT pathway-activated [NGS PIK3CA/AKT1/PTEN-altered] populations) was a secondary endpoint., Results: Median follow-up was 19.0 versus 16.0 months in the ipatasertib-paclitaxel versus placebo-paclitaxel arms, respectively. In the ITT population (n = 124), median OS was numerically longer with ipatasertib-paclitaxel than placebo-paclitaxel (hazard ratio 0.80, 95% CI 0.50-1.28; median 25.8 vs 16.9 months, respectively; 1-year OS 83% vs 68%). Likewise, median OS favored ipatasertib-paclitaxel in the PTEN-low (n = 48; 23.1 vs 15.8 months; hazard ratio 0.83) and PIK3CA/AKT1/PTEN-altered (n = 42; 25.8 vs 22.1 months; hazard ratio 1.13) subgroups. The ipatasertib-paclitaxel safety profile was unchanged., Conclusions: Final OS results show a numerical trend favoring ipatasertib-paclitaxel and median OS exceeding 2 years with ipatasertib-paclitaxel. Overall, results are consistent with the reported PFS benefit; interpretation within biomarker-defined subgroups is complicated by small sample sizes and TNBC heterogeneity., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results